1 Report Overview
1.1 Study Scope
1.2 Key Market Segments
1.3 Players Covered: Ranking by Transdermal Drug Delivery Systems Revenue
1.4 Market by Type
1.4.1 Global Transdermal Drug Delivery Systems Market Size Growth Rate by Type: 2020 VS 2026
1.4.2 Fentanyl
1.4.3 Nitroglycerin
1.4.4 Estradiol
1.4.5 Nicotine
1.4.6 Other
1.5 Market by Application
1.5.1 Global Transdermal Drug Delivery Systems Market Share by Application: 2020 VS 2026
1.5.2 OTC
1.5.3 Rx
1.6 Study Objectives
1.7 Years Considered
2 Global Growth Trends
2.1 Global Transdermal Drug Delivery Systems Market Perspective (2015-2026)
2.2 Global Transdermal Drug Delivery Systems Growth Trends by Regions
2.2.1 Transdermal Drug Delivery Systems Market Size by Regions: 2015 VS 2020 VS 2026
2.2.2 Transdermal Drug Delivery Systems Historic Market Share by Regions (2015-2020)
2.2.3 Transdermal Drug Delivery Systems Forecasted Market Size by Regions (2021-2026)
2.3 Industry Trends and Growth Strategy
2.3.1 Market Top Trends
2.3.2 Market Drivers
2.3.3 Market Challenges
2.3.4 Porter’s Five Forces Analysis
2.3.5 Transdermal Drug Delivery Systems Market Growth Strategy
2.3.6 Primary Interviews with Key Transdermal Drug Delivery Systems Players (Opinion Leaders)
3 Competition Landscape by Key Players
3.1 Global Top Transdermal Drug Delivery Systems Players by Market Size
3.1.1 Global Top Transdermal Drug Delivery Systems Players by Revenue (2015-2020)
3.1.2 Global Transdermal Drug Delivery Systems Revenue Market Share by Players (2015-2020)
3.1.3 Global Transdermal Drug Delivery Systems Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
3.2 Global Transdermal Drug Delivery Systems Market Concentration Ratio
3.2.1 Global Transdermal Drug Delivery Systems Market Concentration Ratio (CR5 and HHI)
3.2.2 Global Top 10 and Top 5 Companies by Transdermal Drug Delivery Systems Revenue in 2019
3.3 Transdermal Drug Delivery Systems Key Players Head office and Area Served
3.4 Key Players Transdermal Drug Delivery Systems Product Solution and Service
3.5 Date of Enter into Transdermal Drug Delivery Systems Market
3.6 Mergers & Acquisitions, Expansion Plans
4 Market Size by Type (2015-2026)
4.1 Global Transdermal Drug Delivery Systems Historic Market Size by Type (2015-2020)
4.2 Global Transdermal Drug Delivery Systems Forecasted Market Size by Type (2021-2026)
5 Market Size by Application (2015-2026)
5.1 Global Transdermal Drug Delivery Systems Market Size by Application (2015-2020)
5.2 Global Transdermal Drug Delivery Systems Forecasted Market Size by Application (2021-2026)
6 North America
6.1 North America Transdermal Drug Delivery Systems Market Size (2015-2020)
6.2 Transdermal Drug Delivery Systems Key Players in North America (2019-2020)
6.3 North America Transdermal Drug Delivery Systems Market Size by Type (2015-2020)
6.4 North America Transdermal Drug Delivery Systems Market Size by Application (2015-2020)
7 Europe
7.1 Europe Transdermal Drug Delivery Systems Market Size (2015-2020)
7.2 Transdermal Drug Delivery Systems Key Players in Europe (2019-2020)
7.3 Europe Transdermal Drug Delivery Systems Market Size by Type (2015-2020)
7.4 Europe Transdermal Drug Delivery Systems Market Size by Application (2015-2020)
8 China
8.1 China Transdermal Drug Delivery Systems Market Size (2015-2020)
8.2 Transdermal Drug Delivery Systems Key Players in China (2019-2020)
8.3 China Transdermal Drug Delivery Systems Market Size by Type (2015-2020)
8.4 China Transdermal Drug Delivery Systems Market Size by Application (2015-2020)
9 Japan
9.1 Japan Transdermal Drug Delivery Systems Market Size (2015-2020)
9.2 Transdermal Drug Delivery Systems Key Players in Japan (2019-2020)
9.3 Japan Transdermal Drug Delivery Systems Market Size by Type (2015-2020)
9.4 Japan Transdermal Drug Delivery Systems Market Size by Application (2015-2020)
10 Southeast Asia
10.1 Southeast Asia Transdermal Drug Delivery Systems Market Size (2015-2020)
10.2 Transdermal Drug Delivery Systems Key Players in Southeast Asia (2019-2020)
10.3 Southeast Asia Transdermal Drug Delivery Systems Market Size by Type (2015-2020)
10.4 Southeast Asia Transdermal Drug Delivery Systems Market Size by Application (2015-2020)
11 India
11.1 India Transdermal Drug Delivery Systems Market Size (2015-2020)
11.2 Transdermal Drug Delivery Systems Key Players in India (2019-2020)
11.3 India Transdermal Drug Delivery Systems Market Size by Type (2015-2020)
11.4 India Transdermal Drug Delivery Systems Market Size by Application (2015-2020)
12 Central & South America
12.1 Central & South America Transdermal Drug Delivery Systems Market Size (2015-2020)
12.2 Transdermal Drug Delivery Systems Key Players in Central & South America (2019-2020)
12.3 Central & South America Transdermal Drug Delivery Systems Market Size by Type (2015-2020)
12.4 Central & South America Transdermal Drug Delivery Systems Market Size by Application (2015-2020)
13 Key Players Profiles
13.1 Hisamitsu
13.1.1 Hisamitsu Company Details
13.1.2 Hisamitsu Business Overview
13.1.3 Hisamitsu Transdermal Drug Delivery Systems Introduction
13.1.4 Hisamitsu Revenue in Transdermal Drug Delivery Systems Business (2015-2020))
13.1.5 Hisamitsu Recent Development
13.2 Mylan
13.2.1 Mylan Company Details
13.2.2 Mylan Business Overview
13.2.3 Mylan Transdermal Drug Delivery Systems Introduction
13.2.4 Mylan Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
13.2.5 Mylan Recent Development
13.3 GSK
13.3.1 GSK Company Details
13.3.2 GSK Business Overview
13.3.3 GSK Transdermal Drug Delivery Systems Introduction
13.3.4 GSK Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
13.3.5 GSK Recent Development
13.4 Novartis
13.4.1 Novartis Company Details
13.4.2 Novartis Business Overview
13.4.3 Novartis Transdermal Drug Delivery Systems Introduction
13.4.4 Novartis Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
13.4.5 Novartis Recent Development
13.5 Teve(Actavis)
13.5.1 Teve(Actavis) Company Details
13.5.2 Teve(Actavis) Business Overview
13.5.3 Teve(Actavis) Transdermal Drug Delivery Systems Introduction
13.5.4 Teve(Actavis) Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
13.5.5 Teve(Actavis) Recent Development
13.6 Johnson & Johnson
13.6.1 Johnson & Johnson Company Details
13.6.2 Johnson & Johnson Business Overview
13.6.3 Johnson & Johnson Transdermal Drug Delivery Systems Introduction
13.6.4 Johnson & Johnson Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
13.6.5 Johnson & Johnson Recent Development
13.7 UCB
13.7.1 UCB Company Details
13.7.2 UCB Business Overview
13.7.3 UCB Transdermal Drug Delivery Systems Introduction
13.7.4 UCB Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
13.7.5 UCB Recent Development
13.8 Teikoku Seiyaku
13.8.1 Teikoku Seiyaku Company Details
13.8.2 Teikoku Seiyaku Business Overview
13.8.3 Teikoku Seiyaku Transdermal Drug Delivery Systems Introduction
13.8.4 Teikoku Seiyaku Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
13.8.5 Teikoku Seiyaku Recent Development
13.9 Bayer
13.9.1 Bayer Company Details
13.9.2 Bayer Business Overview
13.9.3 Bayer Transdermal Drug Delivery Systems Introduction
13.9.4 Bayer Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
13.9.5 Bayer Recent Development
13.10 Lingrui
13.10.1 Lingrui Company Details
13.10.2 Lingrui Business Overview
13.10.3 Lingrui Transdermal Drug Delivery Systems Introduction
13.10.4 Lingrui Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
13.10.5 Lingrui Recent Development
13.11 Sanofi
10.11.1 Sanofi Company Details
10.11.2 Sanofi Business Overview
10.11.3 Sanofi Transdermal Drug Delivery Systems Introduction
10.11.4 Sanofi Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
10.11.5 Sanofi Recent Development
13.12 Qizheng
10.12.1 Qizheng Company Details
10.12.2 Qizheng Business Overview
10.12.3 Qizheng Transdermal Drug Delivery Systems Introduction
10.12.4 Qizheng Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
10.12.5 Qizheng Recent Development
13.13 Endo
10.13.1 Endo Company Details
10.13.2 Endo Business Overview
10.13.3 Endo Transdermal Drug Delivery Systems Introduction
10.13.4 Endo Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
10.13.5 Endo Recent Development
13.14 Huarun 999
10.14.1 Huarun 999 Company Details
10.14.2 Huarun 999 Business Overview
10.14.3 Huarun 999 Transdermal Drug Delivery Systems Introduction
10.14.4 Huarun 999 Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
10.14.5 Huarun 999 Recent Development
13.15 Haw Par
10.15.1 Haw Par Company Details
10.15.2 Haw Par Business Overview
10.15.3 Haw Par Transdermal Drug Delivery Systems Introduction
10.15.4 Haw Par Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
10.15.5 Haw Par Recent Development
13.16 Nichiban
10.16.1 Nichiban Company Details
10.16.2 Nichiban Business Overview
10.16.3 Nichiban Transdermal Drug Delivery Systems Introduction
10.16.4 Nichiban Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
10.16.5 Nichiban Recent Development
13.17 Mentholatum Company
10.17.1 Mentholatum Company Company Details
10.17.2 Mentholatum Company Business Overview
10.17.3 Mentholatum Company Transdermal Drug Delivery Systems Introduction
10.17.4 Mentholatum Company Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
10.17.5 Mentholatum Company Recent Development
13.18 Laboratoires Genevrier
10.18.1 Laboratoires Genevrier Company Details
10.18.2 Laboratoires Genevrier Business Overview
10.18.3 Laboratoires Genevrier Transdermal Drug Delivery Systems Introduction
10.18.4 Laboratoires Genevrier Revenue in Transdermal Drug Delivery Systems Business (2015-2020)
10.18.5 Laboratoires Genevrier Recent Development
14 Analyst’s Viewpoints/Conclusions
15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Disclaimer
15.3 Author Details
【掲載企業】
Hisamitsu、Mylan、GSK、Novartis、Teve(Actavis)、Johnson & Johnson、UCB、Teikoku Seiyaku、Bayer、Lingrui、Sanofi、Qizheng、Endo、Huarun 999、Haw Par、Nichiban、Mentholatum Company、Laboratoires Genevrier
【免責事項】
https://www.globalresearch.jp/disclaimer